UCB Acquires Engage Therapeutics

Eli Lilly Acquires Engage Biologics

May 23, 2026

Biotechnology

Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.

UCB To Acquire Candid Therapeutics for Up to $2.2 Billion

May 3, 2026

Biotechnology

UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.

UCB Acquires Candid Therapeutics

May 3, 2026

Biotechnology

UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engagers for autoimmune and inflammatory diseases, for up to $2.2 billion including $2.0 billion upfront. Two River and Vida Ventures, part of the Bellco Health ecosystem, highlighted their roles in founding and early development of Candid following the announced acquisition.

UCB to Acquire Neurona Therapeutics for up to $1.15 Billion to Advance Epilepsy Cell Therapy

April 21, 2026

Healthcare Services

UCB announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestone payments. The acquisition is intended to strengthen UCB’s epilepsy portfolio and expand it into regenerative medicine via Neurona’s lead cell therapy, NRTX-1001.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

Engrail Therapeutics Acquires NeuroCycle Therapeutics

February 2, 2021

Biotechnology

Engrail Therapeutics has acquired NeuroCycle Therapeutics, a small neuroscience company focused on sub-type selective GABA-A modulation. The acquisition expands Engrail's GABA-A portfolio and provides a platform to advance multiple assets toward clinical trials and further pipeline development.